Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: food

Scientists Say This Simple Supplement May Actually Reverse Heart Disease

Scientists in Japan say a common supplement may actually help “unclog” certain diseased heart arteries from the inside out.

A simple food supplement sold in Japan may have helped reverse a dangerous form of heart disease that often resists standard treatment, according to researchers at Osaka University. The findings, originally published in the European Heart Journal, continue to attract attention because they describe something rarely seen in cardiology: clogged heart arteries becoming noticeably clearer after a nutritional intervention rather than conventional cholesterol lowering alone.

Scientists target a hidden form of heart disease.

Digital therapy outperforms referrals to campus clinics among college students

College students with anxiety, depression and eating disorders may be more likely to start and to respond more positively to therapy offered via a digital app compared to referrals to in-person campus clinics, according to a study led by Penn State researchers and published in the journal Nature Human Behaviour.

Globally, an estimated 40% to 60% of college students experience a mental health disorder at some point, and the need for campus counseling services has increased faster than institutions’ capacity to provide these services, according to the researchers.

The research team wanted to see if a proactive intervention using a digital therapy app could effectively treat anxiety disorders, depression and eating disorders, as well as address the increased need for psychological services.

Harmless viruses trap Salmonella on flexible polymer in portable microfluidic sensor

Researchers at Worcester Polytechnic Institute (WPI) have developed a solid polymer coated with harmless viruses to detect the bacteria Salmonella enterica (S. enterica), an advance that could lead to new ways of finding contamination in the food supply. The work is published in the journal ACS Applied Bio Materials.

The group, led by Yuxiang “Shawn” Liu, an associate professor in the Department of Mechanical and Materials Engineering, reports that the technology can rapidly capture and visualize foodborne bacterial contaminants in tiny fluid samples. With no need for incubation or complicated equipment in research centers, the technology has the potential to be used as a rapid biosensor in field applications and in areas with few resources.

“We have a solid surface that can be used anywhere in the food supply chain, from farm to fridge, to detect foodborne bacteria with minimum human intervention,” Liu says.

FDA Approves Novel Weekly Basal Insulin for T2D

The FDA has approved once-weekly insulin icodec-abae (Awiqli; Novo Nordisk) for use in adults with type 2 diabetes (T2D), with a current projected launch in the second half of 20,261 for the 700-units/mL dose. This novel treatment option is a first-in-its-class therapeutic, freeing patients living with T2D from their strict schedule of daily basal insulin injections and reducing total injections from 7 to 1 for each 7-day period.

Its indication is as an adjunct to diet and exercise for improved glycemic control, as well as for patients also taking mealtime insulin or another common oral antidiabetic agent and/or a glucagon-like peptide-1 receptor agonist. A prescription is required, and administration is with or without food via a prefilled FlexTouch device on the same day each week.

Data from 4 of the trials in the phase 3a ONWARDS program and 2,680 adult patients with uncontrolled T2D support this approval; their primary end point of interest was reduction in hemoglobin A1c. Overall, the ONWARDS program encompasses 6 phase 3a trials and more than 4,000 adults with type 1 diabetes (T1D) or T2D.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

A brain reward circuit inhibited by next-generation weight-loss drugs in mice

New research using humanized mouse models has finally pulled back the curtain on how these small-molecule drugs work in the brain, revealing that they don’t just tell the body it’s full—they actually change how we perceive “treats.”

1. The Homeostatic Circuit: This is the body’s fuel gauge. It involves the hypothalamus and hindbrain, which manage basic hunger and energy levels. It’s the circuit that tells you, “I’ve had enough calories for today.”

These new weight-loss pills do more than just settle your stomach; they speak directly to the brain’s reward center to help quiet the “food noise” that leads to overeating.

This is a “proof of concept” study. It proves the mechanism exists, but it doesn’t yet guarantee that a pill will be a side-effect-free “cure” for overeating in humans.

Humanized glucagon-like peptide 1 receptor (GLP1R) mouse models are used to investigate the neural circuitry through which small-molecule GLP1R agonists modulate feeding, with implications for how these orally delivered weight-loss drugs engage brain reward circuits.

New DNA-Based Therapy Can Help Lower ‘Bad Cholesterol’ Without Statins, Finds Study

Scientists may have found a powerful new way to lower “bad” cholesterol, which did not involve the use of statin medicines. In a recent study, researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was done without the side effects that are often linked to statins. If these results stay consistent in large human trials, the therapy could become an important option for people who cannot tolerate statins or who still have high cholesterol despite taking them. The study was led by Carles J. Ciudad and Veronica Noe from the University of Barcelona’s Faculty of Pharmacy and Food Sciences and the Institute of Nanoscience and Nanotechnology (IN2UB), working with Nathalie Pamir at the University of Oregon in Portland (United States). It was published in the journal Biochemical Pharmacology.

High LDL cholesterol is one of the biggest risk factors for heart attacks and strokes because it leads to the build up fatty plaques in arteries. Drugs like statins work well for many, but some people suffer from muscle aches, digestive issues, or liver problems and have to stop them. However, the new approach is different. Instead of changing how the liver handles fats, it targets a specific protein in the blood that controls how much LDL stays circulating.

Negative effects of artificial sweeteners may pass on to next-generation, study suggests

Health organizations are starting to raise concerns about the potential long-term impacts of artificial sweeteners, which taste sweet but—unlike sugar—contain no calories, suggesting they could interfere with energy metabolism and increase the eventual risk of diabetes or cardiovascular disease.

Now a new study in mice indicates that the popular sweeteners sucralose and stevia have negative effects on the gut microbiome and gene expression, potentially compromising metabolic health, which can be transmitted between generations.

“We found it intriguing that despite the growing consumption of these additives, the prevalence of obesity and metabolic disorders such as insulin resistance has not declined,” said Dr. Francisca Concha Celume of the Universidad de Chile, lead author of the article in Frontiers in Nutrition.

Direct electrochemical appraisal of black coffee quality using cyclic voltammetry

Coffee flavor is primarily determined by the bean roast color and concentration of the beverage. Here, the authors show that both of these characteristics are reflected in the coffee’s cyclic voltammogram. This approach enables rapid determination of the strength and roast intensity of the coffee.

Boosting good gut bacteria population through targeted interventions may slow cognitive decline

The origin of neurodegenerative diseases like Alzheimer’s or dementia isn’t limited to the brain. The state of your gut can quietly set off a cycle of chronic, system-wide inflammation that nudges the brain toward cognitive decline. But how does the pathogenesis of a disease that seems purely brain-based begin in the gut—an organ that is mostly busy producing chemicals for digesting food?

It turns out these two entities are linked by the gut-brain axis, a two-way communication superhighway that constantly sends signals between the digestive tract and the central nervous system. It runs on chemical messengers like neurotransmitters and fatty acids, sharing information that shapes our memory, mood, and inflammation triggers.

An analysis of 15 studies involving more than 4,200 participants found that the gut-brain highway can be put to work as a drug-free route to support cognitive health. Tuning the gut microbiota through diet, supplements, or medical interventions such as fecal microbiota transplantation (FMT) can help improve memory, executive function, and overall cognitive performance, particularly in early or mild cases of cognitive impairment.

/* */